Integrated Strategies for Bioconjugate Development – From Conjugation Chemistry to Clinical Supply

Modern Bioconjugate therapeutics combine complex processes and innovative designs. Smart CMC considerations and scalable, integrated manufacturing are key success factors.

6

May

  • 3PM London / 10AM New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

The rapid expansion of antibody-drug conjugates (ADCs) and novel emerging bioconjugates such as antibody-oligonucleotide conjugates (AOCs) is driving unprecedented CMC complexity. ADCs are a clear success story as they move towards earlier lines of treatment and into non-traditional indications. However, successful development of a bioconjugate therapeutic is no longer just about design innovation. Flawless development and scale-up of complex conjugation technologies is required to deliver on the design promise. Manufacturing expertise, and the ability to reliably deliver GMP product for clinical development and into commercial supply are strategic advantages.

Conor Barry, PhD, Head of R&D – Bioconjugates & Large Molecules at Piramal Pharma Solutions (Grangemouth, UK), will present practical, data-driven insights from integrated bioconjugate programs spanning early development through commercial manufacture. Attendees will gain:

  1. A framework for selecting and optimizing conjugation strategies, including site-specific and enzymatic approaches, to control DAR and product heterogeneity
  2. Case study-driven solutions to payload-linker and analytical challenges, including impurity resolution, chromatography design, and LC-MS characterization in complex systems such as AOCs
  3. An integrated CMC perspective on aligning process development, scale-up, and global manufacturing to enable rapid and robust clinical supply

 

As bioconjugate modalities become more sophisticated, success depends on deep technical expertise combined with tightly integrated development and manufacturing strategies. This webinar will provide actionable insights to help you de-risk complex programs and improve speed to clinic and beyond. Register now to engage with cutting-edge approaches in bioconjugate CMC and stay ahead of evolving technical demands.

Speakers

Select a speaker to learn more

Back
Conor Barry
Global Head of Bioconjugate Development, Piramal

Conor Barry, Ph.D., is the Global Head of Bioconjugate Development at Piramal Pharma Solutions and a valued member of The Science Collective. In his role, Conor oversees our work in antibody-drug conjugates (ADCs), including processing and analytical development of bioconjugates, project scoping, and troubleshooting.

 

Prior to joining Piramal he held senior positions within AstraZeneca, leading ADC Analytical Sciences, and serving on the ADC pipeline leadership team. In this role he helped define the strategy and priorities for ADC development and CMC activities. Previously he worked as a Research Fellow in bioconjugation at Oxford University. Throughout his 19-year career, Conor has amassed an exceptional bioconjugate research and development track record, evidenced by his 23 peer-reviewed scientific publications.

 

While at Piramal Pharma Solutions, his innovative approach contributed to creating ADCelerate, a solution for antibody-drug conjugate drug development that accelerates timelines for developing the initial clinical supply of both drug substance and drug product. As Piramal’s scientific and technical lead on bioconjugates, Conor is well equipped to provide subject matter expertise for our clients.

 

Conor holds a Ph.D. in Organic Chemistry (Bristol), a PG Diploma in Strategy and Innovation (Oxford).

Next speaker

Enquiry